Please assess the completion status of the following clinical trial:

Trial Title: To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* BMI between 18.0 and 29.9 kg/m2, both inclusive, when rounded to the nearest tenth~Exclusion Criteria:~* A medical history and/or condition that is considered significant~* Clinically significant allergic reactions, hypersensitivity~* History or current infection of hepatitis B virus (except for past resolved infection), hepatitis C virus, human immunodeficiency virus, or syphilis~* Active or latent Tuberculosis~* History of malignancy~* Previous monoclonal antibody or fusion protein treatment, or current use of any biologic~* Planning to be pregnant or father a child or donate sperm within 5 month after administration~* Undergone treatment with an investigational drug or participated in another clinical trial within 90 days or 5 half-lives (whichever is longer)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CT-P17 (Type: EXPERIMENTAL): a single subcutaneous (SC) injection via pre-filled syringe (PFS)
- US-licensed Humira (Type: ACTIVE_COMPARATOR): a single subcutaneous (SC) injection via pre-filled syringe (PFS)
- EU-approved Humira (Type: ACTIVE_COMPARATOR): a single subcutaneous (SC) injection via pre-filled syringe (PFS)

Based on this trial design, predict the completion outcome and termination type (if applicable).